Sociodemographic, clinical and therapeutic characteristics, in overall sample and by gender
| Total N: 666 | Male N: 536 (80.5%) | Female N: 130 (19.5%) | p Value | |
|---|---|---|---|---|
| Average age (SD) | 67.4 (12.0) | 66.0 (11.9) | 73.3 (10.6) | <0.001 |
| Median time since coronary event (IQR) | 5.8 (3.5–8.2) | 5.8 (3.5–8.2) | 5.5 (3.8–8.1) | 0.625 |
| Education | ||||
| Illiterate/primary incomplete | 141 (21.2) | 97 (18.1) | 44 (33.8) | <0.001 |
| Completed primary | 435 (65.4) | 357 (66.7) | 78 (60.0) | |
| Secondary or higher | 89 (13.4) | 81 (15.2) | 8 (6.2) | |
| Risk factors | ||||
| Current smoker | 92 (13.8) | 89 (16.6) | 3 (2.3) | <0.001 |
| Arterial hypertension | 585 (88.8) | 464 (87.4) | 121 (95.5) | 0.021 |
| Diabetes mellitus | 230 (34.5) | 174 (32.5) | 56 (43.1) | 0.022 |
| Comorbidity | ||||
| Previous stroke | 41 (6.2) | 24 (4.5) | 17 (13.2) | <0.001 |
| Peripheral artery disease | 13 (2.0) | 13 (2.4) | 0 | 0.083 |
| Chronic kidney disease | 28 (4.2) | 20 (3.7) | 8 (6.2) | 0.217 |
| COPD/asthma | 82 (12.3) | 66 (12.3) | 16 (12.4) | 0.978 |
| Clinical condition | ||||
| Angina | 149 (22.4) | 113 (21.1) | 36 (27.9) | 0.095 |
| Dyspnoea FC (II-IV) | 194 (29.1) | 135 (25.2) | 59 (45.4) | <0.001 |
| FC I | 469 (70.5) | 399 (74.4) | 70 (54.3) | <0.001 |
| FC II | 174 (26.2) | 121 (22.6) | 53 (41.1) | |
| FC III | 16 (2.4) | 13 (2.4) | 3 (2.3) | |
| FC IV | 4 (0.6) | 1 (0.2) | 3 (2.3) | |
| Estimated GFR <60 mL/min | 115 (17.3) | 75 (14.0) | 40 (30.8) | <0.001 |
| Alb/Creat urine >30 mg/g | 111 (16.8) | 83 (15.6) | 28 (22.0) | 0.080 |
| Atrial fibrillation | 49 (7.4) | 33 (6.2) | 16 (12.3) | 0.016 |
| Pacemaker rhythm | 14 (2.1) | 12 (2.2) | 2 (1.5) | 0.618 |
| LDL-C >100 mg/dL | 264 (39.6) | 212 (39.6) | 52 (40.0) | 0.925 |
| HDL-C <40 M, <45 W | 153 (23) | 126 (23.5) | 27 (20.8) | 0.506 |
| TGC=>150 | 172 (25.8) | 138 (25.7) | 34 (26.2) | 0.924 |
| Diagnostic and revascularisation procedure | ||||
| Coronary angiography | 403 (60.5) | 342 (63.8) | 61 (46.9) | 0.001 |
| PCI | 276 (41.4) | 239 (44.6) | 37 (28.5) | 0.001 |
| CABG | 18 (2.7) | 14 (2.6) | 4 (3.1) | 0.769 |
| Current medication | ||||
| Antiplatelet | 586 (88.0) | 475 (88.8) | 111 (86.0) | 0.386 |
| Statins | 575 (86.5) | 465 (86.9) | 110 (84.6) | 0.492 |
| β-blockers | 503 (75.6) | 402 (75.1) | 101 (77.7) | 0.543 |
| ACE inhibitors/ARB | 436 (65.8) | 347 (65.0) | 89 (69.0) | 0.389 |
| Diuretic | 251 (37.9) | 185 (34.6) | 66 (51.2) | 0.001 |
| Calcium channel blocker | 139 (21.0) | 111 (20.8) | 28 (21.9) | 0.794 |
| Transdermal NTG | 75 (11.3) | 58 (10.9) | 17 (13.3) | 0.442 |
| Anticoagulant | 55 (8.3) | 42 (7.9) | 13 (10.1) | 0.414 |
| OAD | 148 (22.2) | 114 (21.3) | 34 (26.2) | 0.229 |
| Insulin | 55 (8.3) | 39 (7.3) | 16 (12.3) | 0.062 |
| OAD or insulin | 173 (26.0) | 132 (24.6) | 41 (31.5) | 0.107 |
Alb/Creat, urine, ratio albuminuria/creatininuria; ARB, angiotensin II receptor blocker; CABG, coronary artery by-pass grafting; COPD, chronic obstructive pulmonary disease; FC, functional classification, classes I-IV according to the American Heart Association; GFR, estimated glomerular filtration rate according to MDRD-IDMS; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; NTG, nitroglycerine; OAD, oral antidiabetic; PCI, percutaneous coronary intervention; TGC, triglycerides.